{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:30:36Z","timestamp":1791070236240,"version":"4.1.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"Importance<\/jats:title>Use of buprenorphine or methadone to treat opioid use disorder is recommended in pregnancy; however, their teratogenic potential is largely unknown.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare the risk of congenital malformations following in utero exposure to buprenorphine vs methadone.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This population-based cohort study used health care utilization data from publicly insured Medicaid beneficiaries in the US from 2000 to 2018. A total of 13\u202f360 pregnancies with enrollment from 90 days prior to pregnancy start through 1 month after delivery and first trimester use of buprenorphine or methadone were included and linked to infants. Data were analyzed from July to December 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>A pharmacy dispensing of buprenorphine or a code for administration of methadone in the first trimester.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes included major malformations overall and malformations previously associated with opioids (any cardiac malformations, ventricular septal defect, secundum atrial septal defect\/nonprematurity-related patent foramen ovale, neural tube defects, clubfoot, and oral clefts). Secondary outcomes included other organ system\u2013specific malformations. Risk differences and risk ratios (RRs) were estimated comparing buprenorphine with methadone, adjusting for confounders with propensity score overlap weights.<\/jats:p><\/jats:sec>Results<\/jats:title>The cohort included 9514 pregnancies with first-trimester buprenorphine exposure (mean [SD] maternal age, 28.4 [4.6] years) and 3846 with methadone exposure (mean [SD] maternal age, 28.8 [4.7] years). The risk of malformations overall was 50.9 (95% CI, 46.5-55.3) per 1000 pregnancies for buprenorphine and 60.6 (95% CI, 53.0-68.1) per 1000 pregnancies for methadone. After confounding adjustment, buprenorphine was associated with a lower risk of malformations compared with methadone (RR, 0.82; 95% CI, 0.69-0.97). Risk was lower with buprenorphine for cardiac malformations (RR, 0.63; 95% CI, 0.47-0.85), including both ventricular septal defect (RR, 0.62; 95% CI, 0.39-0.98) and secundum atrial septal defect\/nonprematurity-related patent foramen ovale (RR, 0.54; 95% CI, 0.30-0.97), oral clefts (RR, 0.65; 95% CI, 0.35-1.19), and clubfoot (RR, 0.55; 95% CI, 0.32-0.94). Results for neural tube defects were uncertain given low event counts. In secondary analyses, buprenorphine was associated with a decreased risk of central nervous system, urinary, and limb malformations but a greater risk of gastrointestinal malformations compared with methadone. These findings were consistent in sensitivity and bias analyses.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study, the risk of most malformations previously associated with opioid exposure was lower in buprenorphine-exposed infants compared with methadone-exposed infants, independent of measured confounders. Malformation risk is one factor that informs the individualized patient decision regarding medications for opioid use disorder in pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamainternmed.2023.6986","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T16:31:59Z","timestamp":1705941119000},"page":"242","source":"Crossref","is-referenced-by-count":29,"title":["First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations"],"prefix":"10.1001","volume":"184","author":[{"given":"Elizabeth A.","family":"Suarez","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey"},{"name":"Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreen","family":"Straub","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendr\u00e9e E.","family":"Jones","sequence":"additional","affiliation":[{"name":"UNC Horizons Program, Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Gray","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary S.","family":"Connery","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Tufts Medical Center and the Tufts Clinical and Translational Science Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Lester","sequence":"additional","affiliation":[{"name":"Center for the Study of Children at Risk, Departments of Psychiatry and Pediatrics, Alpert Medical School of Brown University and Women and Infants Hospital, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishka","family":"Terplan","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanna M.","family":"Vine","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mogun","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista F.","family":"Huybrechts","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"ioi230085r1","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017.","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"ioi230085r2","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1097\/AOG.0000000000002235","article-title":"Committee opinion No. 711: opioid use and opioid use disorder in pregnancy.","volume":"130","author":"Committee on Obstetric Practice American Society of Addiction Medicine","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"22","key":"ioi230085r3","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","article-title":"Buprenorphine versus methadone for opioid use disorder in pregnancy.","volume":"387","author":"Suarez","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"ioi230085r4","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa1005359","article-title":"Neonatal abstinence syndrome after methadone or buprenorphine exposure.","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"ioi230085r5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-050279","article-title":"Opioid use disorder and perinatal outcomes.","volume":"148","author":"Piske","year":"2021","journal-title":"Pediatrics"},{"issue":"12","key":"ioi230085r6","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/add.v111.12","article-title":"Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.","volume":"111","author":"Zedler","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"ioi230085r7","doi-asserted-by":"publisher","first-page":"314.e1","DOI":"10.1016\/j.ajog.2010.12.039","article-title":"Maternal treatment with opioid analgesics and risk for birth defects.","volume":"204","author":"Broussard","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"ioi230085r8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0165-0173(01)00160-6","article-title":"The biology of the opioid growth factor receptor (OGFr).","volume":"38","author":"Zagon","year":"2002","journal-title":"Brain Res Brain Res Rev"},{"issue":"6","key":"ioi230085r9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067405","article-title":"Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations.","volume":"8","author":"Palmsten","year":"2013","journal-title":"PLoS One"},{"key":"ioi230085r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2023.12.001","article-title":"Is there a disparity in medications for opioid use disorder based on race\/ethnicity and gender? a systematic review and meta-analysis.","author":"Nedjat","year":"2023","journal-title":"Res Social Adm Pharm"},{"issue":"6","key":"ioi230085r12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-4131","article-title":"Maternal use of opioids during pregnancy and congenital malformations: a systematic review.","volume":"139","author":"Lind","year":"2017","journal-title":"Pediatrics"},{"issue":"5","key":"ioi230085r13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/AOG.0b013e3182a603bb","article-title":"Development of a comorbidity index for use in obstetric patients.","volume":"122","author":"Bateman","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"25","key":"ioi230085r14","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.v28:25","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"ioi230085r15","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"4","key":"ioi230085r16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"issue":"3","key":"ioi230085r17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies.","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"4","key":"ioi230085r18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7","key":"ioi230085r19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/aje\/kwu190","article-title":"Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis.","volume":"180","author":"Brogly","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"11","key":"ioi230085r20","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-017-0763-8","article-title":"A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates.","volume":"77","author":"Kelty","year":"2017","journal-title":"Drugs"},{"key":"ioi230085r21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4137\/SART.S23547","article-title":"Birth and neonatal outcomes following opioid use in pregnancy: a Danish population-based study.","volume":"9","author":"N\u00f8rgaard","year":"2015","journal-title":"Subst Abuse"},{"issue":"3","key":"ioi230085r22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jpedsurg.2022.08.016","article-title":"Perinatal risk factors for infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis.","volume":"58","author":"Obaid","year":"2023","journal-title":"J Pediatr Surg"},{"issue":"9","key":"ioi230085r23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.jpedsurg.2017.02.017","article-title":"Perinatal risk factors for infantile hypertrophic pyloric stenosis: a meta-analysis.","volume":"52","author":"Zhu","year":"2017","journal-title":"J Pediatr Surg"},{"issue":"3","key":"ioi230085r24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00431-018-3287-7","article-title":"Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis.","volume":"178","author":"Abdellatif","year":"2019","journal-title":"Eur J Pediatr"},{"issue":"8","key":"ioi230085r25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jpedsurg.2014.01.053","article-title":"Maternal and pregnancy characteristics and risk of infantile hypertrophic pyloric stenosis.","volume":"49","author":"Svenningsson","year":"2014","journal-title":"J Pediatr Surg"},{"issue":"5","key":"ioi230085r26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/humupd\/dmr022","article-title":"Maternal smoking in pregnancy and birth defects: a systematic review based on 173?687 malformed cases and 11.7 million controls.","volume":"17","author":"Hackshaw","year":"2011","journal-title":"Hum Reprod Update"},{"issue":"2","key":"ioi230085r27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/archpediatrics.2011.185","article-title":"Reduced risks of neural tube defects and orofacial clefts with higher diet quality.","volume":"166","author":"Carmichael","year":"2012","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"1","key":"ioi230085r28","doi-asserted-by":"publisher","first-page":"F43","DOI":"10.1136\/archdischild-2014-308013","article-title":"Lower rate of selected congenital heart defects with better maternal diet quality: a population-based study.","volume":"101","author":"Botto","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"11","key":"ioi230085r29","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/add.v115.11","article-title":"Alcohol use in pregnancy and its impact on the mother and child.","volume":"115","author":"Oei","year":"2020","journal-title":"Addiction"},{"issue":"1","key":"ioi230085r30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13722-016-0070-9","article-title":"Prenatal treatment for opioid dependency: observations from a large inner-city clinic.","volume":"12","author":"Saia","year":"2017","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"ioi230085r31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/EDE.0000000000000780","article-title":"Methadone versus buprenorphine for opioid use dependence and risk of neonatal abstinence syndrome.","volume":"29","author":"Lemon","year":"2018","journal-title":"Epidemiology"},{"key":"ioi230085r32","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1111\/nure.2013.71.issue-s1","article-title":"Prepregnancy obesity and the risk of birth defects: an update.","volume":"71","author":"Correa","year":"2013","journal-title":"Nutr Rev"},{"issue":"1","key":"ioi230085r33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","article-title":"No adjustments are needed for multiple comparisons.","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"issue":"3","key":"ioi230085r34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jsat.2007.10.007","article-title":"Treatment of opioid-dependent pregnant women: clinical and research issues.","volume":"35","author":"Jones","year":"2008","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"ioi230085r36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ajog.2022.05.041","article-title":"Buprenorphine uptake during pregnancy following the 2017 guidelines update on prenatal opioid use disorder.","volume":"227","author":"Nguemeni Tiako","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"ioi230085r11","unstructured":"Data Quality Atlas. Centers for Medicare & Medicaid Services. Accessed December 12, 2023. https:\/\/www.medicaid.gov\/dq-atlas\/welcome"},{"key":"ioi230085r35","unstructured":"Consolidated Appropriations Act, HR 2617, 117th Cong (2021). Pub L No. 117-328. Accessed December 10, 2023. https:\/\/www.congress.gov\/bill\/117th-congress\/house-bill\/2617"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2814227\/jamainternal_suarez_2024_oi_230085_1719857544.44181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:30:28Z","timestamp":1719858628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2814227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2023.6986","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}